Solomon L, Finegan K
S Afr Med J. 1981 Sep 5;60(10):384-6.
Fenbufen (3(4-biphenyl-carbonyl) propionic acid) (Cinopal; Lederle) was administered as a single daily dose of 1000 mg for 4 weeks to 20 patients with rheumatoid arthritis. At 2 weeks, and again at the end of the trial, patients were assessed for duration of morning stiffness, number of painful and/or swollen joints, grip strength, walking time, and subjective response to treatment. Four patients failed to complete the trial, 2 because of inability to control symptoms and 2 because of severe rash attributed to the drug. The remaining 16 patients showed some improvement in most of the recorded parameters, with statistically significant reduction of morning stiffness and walking time. Apart from a maculopapular rash, which occurred in 4 patients and cleared up on stopping the fenbufen, side-effects were minimal. No patient complained of dyspepsia or epigastric pain.
给20例类风湿性关节炎患者每日单次服用1000毫克联苯丁酮酸（3-(4-联苯甲酰基)丙酸）（西诺帕；莱德利公司生产），持续4周。在第2周以及试验结束时，对患者的晨僵持续时间、疼痛和/或肿胀关节数量、握力、步行时间以及对治疗的主观反应进行评估。4例患者未能完成试验，2例是因为症状无法控制，2例是由于药物引起的严重皮疹。其余16例患者在大多数记录参数上有一定改善，晨僵和步行时间有统计学意义的缩短。除4例患者出现斑丘疹皮疹，停药后消退外，副作用极小。没有患者抱怨消化不良或上腹部疼痛。
